A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC): Genomic sequencing and updated efficacy results Meeting Abstract
| Authors: | O'Cearbhaill, R. E.; Homicsko, K.; Wolfer, A.; DiSilvestro, P. A.; O'Malley, D. M.; Sabbatini, P.; Orcurto, A.; Barras, D.; Shohara, L.; Ricciardi, T.; Macri, M.; Ryan, A.; Venhaus, R. R.; Monk, B. J.; Coukos, G. |
| Abstract Title: | A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC): Genomic sequencing and updated efficacy results |
| Meeting Title: | 51st Annual Meeting of the Society of Gynecologic Oncology (SGO) |
| Journal Title: | Gynecologic Oncology |
| Volume: | 159 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Mar 28-31 |
| Meeting Location: | Toronto, Canada |
| ISSN: | 0090-8258 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2020-01-01 |
| Start Page: | 41 |
| End Page: | 41 |
| Language: | English |
| ACCESSION: | WOS:000579556200082 |
| DOI: | 10.1016/j.ygyno.2020.06.086 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 51 -- This meeting was cancelled due to COVID-19 -- Source: Wos |
